This patent review focuses exclusively on the oral delivery of mesalamine (5-ASA) and excludes oral mesalamine
pro-drug and rectal delivery formulations. The formulation strategies of marketed formulations (Apriso®, Asacol®,
Lialda® and Pentasa®) and non-marketed formulations are reviewed and explained by decoding formulation specifics that
enable the site specific delivery for the treatment of inflammatory bowel disease.
Keywords: Apriso, asacol, asacol HD, 5-ASA, Crohn’s disease and ulcerative colitis, inflammatory bowel disease, lialda, mesalamine,
oral delivery, pentasa.
Rights & PermissionsPrintExport